Takeda Oncology, the Global Oncology Business Unit of Takeda Pharmaceutical, is headquartered in Cambridge, Massachusetts, on our legacy site of Millennium Pharmaceuticals.
As a legacy genomics company, Millennium Pharmaceuticals, founded in 1993, applied world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over the past two decades, Millennium became a fully integrated biopharmaceutical company, and introduced its first successfully commercialized medicine. Millennium was subsequently acquired by Takeda Pharmaceutical Company Limited in 2008 forming Millennium: The Takeda Oncology Company.
2014 was another hallmark year for Millennium: The Takeda Oncology Company. With its reputable history in oncology, the Cambridge site became the global headquarters for Takeda's oncology-focused business unit and was rebranded as Takeda Oncology, which aims to unify our operations across our ever-expanding global footprint.
Currently, Takeda Oncology includes hubs in seven countries: the United States, Japan, the United Kingdom, Germany, France, Brazil, and Indonesia, each selected for their representative oncology market. Our business model is designed to maximize our local and global capabilities and to drive oncology business across all of our diverse markets. With this structure in place, we are optimally organized to discover, develop and deliver best-in-class oncology therapies for patients around the world.
As Takeda Oncology continues to grow, we will maintain the agile, entrepreneurial spirit that helped us grow into the leader in oncology that we are today. Our commitment and tireless focus on improving treatment options for cancer patients are unwavering.